AESI	adverse event of special interest
ALLSTAR	Austrian Radio-Oncological Lung Cancer Study Association Registry
BH	Benjamini–Hochberg
BICR	blinded independent centralized review
cCRT	concomitant chemoradiotherapy
CRIT	chemoradioimmunotherapy
CRT	chemoradiotherapy
EAP	early-access programme
EMA	European Medicines Agency
EQD2	biologically equivalent dose in 2 Gy fractions
GTV	gross tumour volume
ICI	immune-checkpoint inhibitor
ITC	intrathoracic tumour control
IMRT	intensity-modulated radiotherapy
LC	local control
MHC	major histocompatibility complex
MVA	multivariate analysis
NSCLC	non-small-cell lung cancer
OS	overall survival
PD-L1	programmed death ligand 1
PFS	progression-free survival
RT	radiotherapy
RWD	real-world data
RMST	restricted mean survival time
sCRT	sequential chemoradiotherapy
SoC	standard of care
TDLR	time to death or local relapse
TMB	tumour mutational burden
TME	tumour microenvironment
TTDM	time to death or distant metastasis
UVA	univariate analysis
VMAT	volumetric arc therapy